Moderna Climbs 13% After Analyst Upgrades to a Buy: Why MRNA is Still Rated a Hold at VectorVest
Shares of Moderna (MRNA) climbed 13% in yesterday’s trading session after being upgraded to a buy at Oppenheimer. The stock fell a bit in Wednesday’s trading session, but has since settled at around even on the day. Hartaj Singh and a team of analysts see dramatic upside potential over the next few years for [...]